Results 81 to 90 of about 737 (141)

Cover Picture: Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
In the cohort of SARS‐CoV‐2 infected patients with pre‐existing chronic respiratory diseases, azvudine can not only relieve disease symptoms by blocking the activity of the viral RNA polymeraseand inhibiting viral replication, but also perform immune‐enhancing effect by increasing the number and function of serum lymphocytes, and thus activating the ...
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
wiley   +1 more source

Clinical characteristics, diagnosis and short‐term outcomes of COVID‐19–associated acute myocarditis in China

ESC Heart Failure, Volume 12, Issue 1, Page 338-352, February 2025.
Abstract Aims Acute myocarditis (AM) has been recognized as a rare complication of coronavirus disease 2019 (COVID‐19) infection. This study was conducted to present the clinical characteristics, disease courses and short‐term prognoses of Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) induced AM in China, which has ...
Huihui Liu, Ping Zhou, Yan Huang, Sulan Yan, Lei Zhou, Chuanyu Gao, Lian Wang, Jianjun Tang, Qiong Zhou, Xinqing Li, Xiaofeng Zhuang, Mei Zhai, Liyan Huang, Xuemei Zhao, Barry Greenberg, David H. Hsi, Yuhui Zhang, Jian Zhang   +17 more
wiley   +1 more source

Clinical Characteristics During and After COVID‐19 Infection Among Healthcare Workers During the First Wave of Omicron in Chongqing, China

Immunity, Inflammation and Disease, Volume 13, Issue 1, January 2025.
Our study provides a comprehensive depiction of the clinical symptoms experienced by healthcare workers during and after SARS‐CoV‐2 infection in China's Omicron wave, shedding light on the intricate interplay between these symptoms and offering novel insights into the physiological impact of SARS‐CoV‐2 on human health.
Haoling Tang, Zhiwei Chen, Tianquan Huang, Pingping Yu, Qiao Tang, Yue Qiu, Yunling Xue, Jing Tang, Nan Cai, Hong Ren, Mingli Peng, Peng Hu   +11 more
wiley   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

The Role of Ursodeoxycholic Acid Administration During the COVID‐19 Pandemic: A Questionnaire Survey

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2025, Issue 1, 2025.
In December 2022, China classified COVID‐19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID‐19. The objective of this questionnaire was to assess the infection status in the COVID‐19 pandemic since December in Henan Province, China, and the prevalence of infection in people who were taking ...
Cheng Zhou, Ran Jia, Jinqiu Yang, Tong Liu, Xiaoyan Liu, Lin Yang, Wenxia Zhao, Jess Vergis   +7 more
wiley   +1 more source

Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

Influenza and Other Respiratory Viruses, Volume 18, Issue 12, December 2024.
ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive.
Nida Kalam, Vinod R. M. T. Balasubramaniam   +1 more
wiley   +1 more source

A Study on the Efficacy of Early Application of Azvudine in Viral Myocarditis under the Epidemic

Journal of Medicines Development Sciences
Objective: To explore the efficacy of early application of Azvudine in patients with viral myocarditis during the epidemic. Methods: Sixty patients diagnosed with "infection complicated with myocarditis" in our hospital from December 2022 to December 2023 were selected and randomly divided into an intervention group and a control ...
Minjie Wu, Linlin Tan, Anjian Yan
openaire   +1 more source

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment [PDF]

Signal Transduction and Targeted Therapy, 2020
Yu, Bin, Chang, Junbiao
openaire   +2 more sources

Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies

The Clinical Respiratory Journal
ABSTRACTBackgroundAzvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are still unclear.
Tao Dong, Wentao Zhang, Tingting Wu, Yongxiang Ge, Qi Yang, Jia Xu, Yuna Liu   +6 more
openaire   +3 more sources

Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial [PDF]

Background Severe acute respiratory syndrome coronavirus 2 will coexist with humans for a long time, and it is therefore important to develop effective treatments for coronavirus disease 2019 (COVID-19).
Huaiya Xie, Yongjian Liu, Chongya Dong, Xinlun Tian, Xueqi Liu, Aohua Wu, Xiaoyan Yan, Mengzhao Wang, Siqi Pan, Luo Wang, Yaqi Wang, Jinglan Wang, Hong Zhang, Chen Yao, Junping Fan, Yan Xu   +15 more
core   +1 more source